Antiretroviral treatment French guidelines 2013: economics influencing science.
Guidelines for the preferred choice of initial combination antiretroviral therapy in those living with HIV are provided by several national and international committees. Following the recent presentation of the 2013 French guidelines on antiretroviral therapy, there has been a debate regarding whether and/or how economics should influence guideline decisions and to what extent this should counterbalance valid scientific evidence. We discuss here the reasons for the unique nature of some of the proposals made by the French guidelines panel. Indeed, some recommendations are debatable. In the new French guidelines, economic considerations significantly influence and, in some instances, take precedence over the scientific evidence, leading to guidelines that are significantly different from those of other national and international committees.
Infectious Diseases, University Hospital, Nantes, France.
F
F
Raffi
J
J
Reynes
D044966:Anti-Retroviral Agents / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics / Q000379:methods* / Q000592:standards*; D015658:HIV Infections / Q000188:drug therapy*; D006291:Health Policy; D006801:Humans; D017410:Practice Guidelines as Topic
D044966:Anti-Retroviral Agents
ART; antiretroviral therapy; cost-effectiveness; high-income countries; preferred regimens